Trial · NCT06398444
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and severity of adverse events (AE) (Part1) | Until 6 months after the last dose | |
| Primary | Overall Response Rate (ORR) assessed by Independent Review Committee (IRC) (Part 2) | Until disease progression or death, up to 5 years | |
| Secondary | Overall Response Rate (ORR) (Part 1) | Until disease progression or death, up to 5 years | |
| Secondary | Progression-free survival (PFS) (Part 1) | Until disease progression or death, up to 5 years | |
| Secondary | Disease Control Rate (DCR) (Part 1) | Until disease progression or death, up to 5 years | |
| Secondary | Duration of Overall Response (DoR) (Part 1) | Until disease progression or death, up to 5 years | |
| Secondary | Time to Progression (TTP) (Part 1) | Until disease progression or death, up to 5 years | |
| Secondary | PFS rate at 12 months (Part 1) | At 12 months after the first dose | |
| Secondary | Overall Survival (OS) (Part 1) | Until death of any cause, up to 5 years | |
| Secondary | Change From Baseline in the EORTC QLQ-C30 Questionnaire (Part 1) | Until disease progression or death, up to 5 years | |
| Secondary | Change From Baseline in the EORTC Quality of Life Questionnaire (Part 1) | Until disease progression or death, up to 5 years | |
| Secondary | ORR assessed by investigators (part 2) | Until disease progression or death, up to 5 years | |
| Secondary | Progression-free survival (PFS) (Part 2) | Until disease progression or death, up to 5 years | |
| Secondary | Disease Control Rate (DCR) (Part 2) | Until disease progression or death, up to 5 years | |
| Secondary | Duration of Overall Response (DoR) (Part 2) | Until disease progression or death, up to 5 years | |
| Secondary | Overall Survival (OS) (Part 2) | Until death of any cause, up to 5 years | |
| Secondary | Change From Baseline in the EORTC QLQ-C30 Questionnaire (Part 2) | Until disease progression or death, up to 5 years | |
| Secondary | Change From Baseline in the EORTC Quality of Life GI.NET21 Questionnaire (Part 2) | Until disease progression or death, up to 5 years | |
| Secondary | Incidence and severity of AE (Part2) | Until 6 months after the last dose | |
| Secondary | The proportion of subjects with a reduction of at least 50% from baseline in antihypertensive medication that was sustained for more than 6 months (evaluated only in subjects with hypertension) | Until disease progression or death, up to 5 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06398444/registered